US$ 20.94
glp-1 receptor agonists weight loss For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH Comparing GLP-type therapies for weight
Description
Ans: Ozempic dominated with approximately 35.12% share in 2025
Ozempic and Mounjaro are brand names used for those with diabetes

Side effect profile

Switching to oncedaily liraglutide from twicedaily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents

[DOI] [PMC free article] [PubMed] [Google Scholar] 144.Chirila A., Nguyen M.E., Tinmouth J., Halperin I.J
